Evaluating BDNF Biomarkers in Cerebrospinal Fluid for Huntington's Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the levels of Brain Derived Neurotrophic Factor (BDNF) in the cerebrospinal fluid of patients with Huntington's Disease (HD) to explore its potential as a biomarker for the BDNF-TrkB signaling pathway. It is a multicenter, prospective case-control study involving several university hospitals in France. The study will also evaluate plasma BDNF levels, correlate these with clinical severity and brain MRI parameters, and confirm the presence of other neuronal degeneration markers. Participants will include genetically confirmed HD patients and control subjects who have undergone lumbar puncture for medical reasons.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* General inclusion criteria:

  * age ≥ 18 years-old
  * national health insurance cover
* Patients inclusion criteria:

  * genetically confirmed Huntington's disease diagnosis (≥ 35 CAG repeat in HTT gene exon 1)
  * written informed consent
  * only for patients "with lumbar puncture (LP)": patient agreement for LP
* Control inclusion criteria:

  * anterior LP for medical reason with consent for biobank "Neuro" with following samples present in this biobank : 2 mL blood + 0.5 mL plasma + 0.5 mL cerebrospinal fluid
  * information and non-opposition for the finality of this biobank
  * paired by age with a patient (+/- 5 years difference)

Exclusion Criteria:

* General exclusion criteria:

  * protected by law
* Patients exclusion criteria:

  * Huntington's disease stage too Evolved that may interfere with cognitive evaluations or MRI
  * contraindications to brain MRI
  * only for patients "with LP": contraindications to LP
  * incapacity to give informed consent
* Control exclusion criteria:

  * neurodegenerative of inflammatory central nervous system pathology

Where it's running

• University Hospital of Montpellier
  Montpellier, France Recruiting

Study contacts

• Study coordinator: Cecilia MARELLI, MD
• Email: c-marelli@chu-montpellier.fr
• Phone: +33(0)467336029

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pridopidine for Huntington's Disease: a 1-year, randomized, placebo-controlled study

  This trial tests whether pridopidine can slow the progression of Huntington's disease in adults compared with placebo over one year.

  Recruiting at 17 sites Phase 3 Prilenia · Birmingham, Alabama and 65 other locations · NCT07609108

• Low-intensity focused ultrasound targeting the globus pallidus to improve movement in Huntington's disease

  This trial tests whether different pulse frequencies of low-intensity focused ultrasound (LIFU) aimed at a deep brain target can safely reduce chorea and other motor symptoms in adults with Huntington's disease.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07513844

• Safety and tolerability of human neural stem cell implants for Huntington's disease

  This research will test whether an implant of hNSC-01 human neural stem cells is safe and tolerable for adults with Huntington's disease.

  Recruiting Phase 1/2 University of California, Irvine · Irvine, California · NCT07451613

• SKY-0515 for adults with Huntington's disease

  This trial will test whether the oral drug SKY-0515 can lower harmful huntingtin protein and improve symptoms in adults aged 25 and older with genetically confirmed Huntington's disease.

  Recruiting at 19 sites Phase 2/3 Skyhawk Therapeutics, Inc. · Englewood, Colorado and 30 other locations · NCT07378644

• Votoplam for adults with early symptomatic Huntington's disease

  This trial will test whether votoplam (HTT227) is safe and can slow disease progression in adults with early symptomatic Huntington's disease.

  Recruiting at 117 sites Phase 3 Novartis · Birmingham, Alabama and 116 other locations · NCT07326709

• Comparing three social cognition tests in adults with early Huntington disease

  This project will test whether the DMASC-MC and two established social cognition tests can detect social thinking problems in adults with early Huntington disease.

  Recruiting Region Skane · Lund · NCT07253038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.